14 tai lieu tham khao

TÀI LIỆU THAM KHẢO
1. Corcos J, Schick E (2008), Simplified anatomy of the vesico–urethral
functional unit.

Textbook of neurogenic Bladder; UK, Informa

Healthcare: 2: 13-18
2. Harrington A, Bhandary A (2011), Neurogenic Detrusor Overactivity
After Spinal Cord Injury. University of Pittsburgh School of Medicine
Rehab Grand Rounds: 1-8
3. Dahlberg A, Perttila I, Wuokko E et al. (2004), Bladder management in
persons with spinal cord lesion. Spinal Cord 42: 694-698
4. Giannantoni A, Mearini E, Zingaro MD et al. (2009), Six-Year FollowUp of Botulinum Toxin A Intradetrusorial Injections in Patients with
Refractory Neurogenic Detrusor Overactivity : Clinical and Urodynamic
Results. European urology; 55: 705–712
5. Ku JH (2006), The management of neurogenic bladder and quality of life
in spinal cord injury; Journal compilation BJU International; 98:739–745
6. Shin JC, Chang WH, Jung TH et al. (2008), The determination of
sensation-dependent bladder emptying time in patients with complete
spinal cord injury above T11. Spinal Cord; 46: 210–215
7. Giannantoni A, Mearini E, Del Zingaro M et al. (2008), Botulinum A
toxin in the treatment of neurogenic detrusor overactivity: a consolidated
field of application. BJU Iternational; 102, supplement 1, 2–6
8. Lee CH, Yeh CH (2011), Treatment of Voiding Dysfunction in
Neurogenic Bladder; Incont Pelvic Floor Dysfunct; 5(1):13-16
9. Amend B, Hennenlotter J, Schafer T et al. (2008), Effective Treatment of
Neurogenic

Detrusor

Dysfunction

by

Combined

High-Dosed

Antimuscarinics without Increased Side-Effects. European Urology;53:
1021–1028


10. Gulur, Drake (2010), Management of overactive bladder. Review
Urology; 7: 572–582
11. Lee CH, Yeh CH (2011), Treatment of Voiding Dysfunction in
Neurogenic Bladder; Incont Pelvic Floor Dysfunct; 5(1):13-16
12. Del Popolo G, Mencarini M, Nelli F et al. (2012), Controversy over the
pharmacological treatments of storage symptoms in spinal cord injury
patients: A literature overview. Spinal Cord; 50: 8–13
13. Kuo HC (2010), Intravesical Treatment for Overactive Bladder
Refractory to Antimuscarinics. Incontinence Pelvic Floor Dysfunction;
4(1): 5-9
14. Schurch B, de Seze M, Denys P et al. (2005), Botulinum toxin type a is a
safe and effective treatment for neurogenic urinary incontinence: results
of a single treatment, randomized, placebo controlled 6-month study. J
Urol. 174: 196-200
15. Smith CP, Gangitano DA , Munoz A et al. (2008), Botulinum toxin type
A normalizes alterations in urothelial ATP and NO release induced by
chronic spinal cord injury. Neurochemistry International;52:1068–1075
16. Thavaseelan J (2007), Botulinum Toxin Treatment for Neurogenic
Detrusor Overactivity. Incont Pelvic Floor Dysfunct;1:1-3

17. Nguyễn Xuân Nghiên, Cao Minh Châu và cộng sự (2002), Vật lý trị liệu,
phục hồi chức năng. NXB y học: tr 615
18. Kirshblum S (2005), Rehabilitation of Spinal Cord Injury. Physical
Medicine and Rehabilitation by Lippincott Williams &Wilkins; 2: 17151720.
19. Sinha D (2004), Prevention of spinal cord injury in developing countrie;
4 th Asian SpinL Cord Netk Conference in Kathmandu Nepal; 63 - 66
20. Gwynedd E. Pickett, MD, FRCSC et al. (2006), Epidemiology of
Traumatic Spinal Cord Injury in Canada. Spine Volume 31, Number 7:
799–805


21. Schoenfeld AJ, McCriskin B, Hsiao M, et al. (2011), Incidence and
epidemiology of spinal cord injury within a closed American population:
the United States military (2000–2009); Spinal Cord, 49, pp. 874–879
22. Vũ Thị Hiền Trinh, Cao Minh Châu (2005), Nghiên cứu dịch tễ học lâm
sàng và kết quả phục hồi chức năng cho bệnh nhân tổn thương tủy sống
tại Trung tâm Phục hồi chức năng bệnh viện Bạch Mai. Luận văn tốt
nghiệp bác sỹ đa khoa, Đại học Y Hà Nội
23. De Groat WC, Yoshimura N (2012), Plasticity in reflex pathways to the
lower urinary tract following spinal cord injury; Experimental Neurology;
235: 123–132
24. Michel MC, Oelkeb M, Peters S (2005), The Neuro-Urological
Connection. European Urology Supplements 4: 18–28
25. Abrams P and Karl-Erik A (2007), Muscarinic receptor antagonists for
overactive bladder. Journal compilation BJU International; 100: 9871006
26. Valentino RJ, Susan KW, Alan JW et al. (2011), The bladder - brain
connection: putative role of corticotrophin - releasing factor. Urology; 8:
19–28
27. De Groat WC, Yoshimura N (2010), Changes in Afferent Activity After
Spinal Cord Injury. Neurourology Urodynamics; 29(1): 63–76

28. Fowler CJ, Griffiths D and de Groat WC (2008), The neural control of
micturition. Nat Rev Neurosci; 9(6): 453–466
29. Abrams P, Artibani W, Cardozo L et al. (2005), Clinical manual of
incontinence in women. Health publication; 1: 6-15
30. Joseph G, Ouslander JG (2004), Management of Overactive Bladder. The
New England Journal of Medicine; 7: 786- 792
31. Birder LA and Groat WC (2007), Mechanisms of Disease: involvement
of the urothelium in bladder dysfunction. Nature clinical practice
urology; vol.4; No.1: 1-4


32. Dorsher PT and Mc Intosh PM (2012), Review Article Neurogenic
Bladder. Advances in Urology Volume 2012; No.10: 1-16
33.Huang ST (2008), The Role of Antimuscarinics in the Treatment of
Neurogenic Detrusor Overactivity in Patients with Stroke, Spinal Cord
Injury and Parkinson's Disease. Incont Pelvic Floor Dysfunct; 2 (Suppl
1): 25-28
34. Linsenmeyer T, Maddox S, et al. (2006), Bladder Management
Following Spinal Cord Injury: What You Should Know. A Guide for
People with Spinal Cord Injury. Spinal Cord Medicine;35: 1-36.
35.Wyndaele J.J, Kovindha A, Igawa Y et al. (2010), Neurologic Urinary
and Faecal Incontinence; Neurourology and Urodynamics; 29: 207–212
36. Abrams P, Cardozo L, Fall M, et al. (2002), The standardisation of
terminology in lower urinary tract function: report from

the

standardisation sub-committee of the International Continence Society.
Neurourology & Urodynamics; 21(2):167-78
37. Abrams P (2006), Urodynamics; Springer-Verlag London Limited:1-147

38. Blaivas J, Chancellor M, Weiss J et al. (2007), Atlas of urodynamics;
Lippincott Williams & Wilkins.1-239
39. GÜMÜŞ D, BAĞDATLI Y (2010), A bacteriological examination of
urine before and after urodynamic testing. Turk J Med Sci 40 (2): 317-322
40. Quek P, Tay LH (2004), Morbidity and Significant Bacteriuria after
Urodynamic Studies. Ann Acad Med Singapore; 33: 754-7
41. Taweel WA, Alkhayal A (2011), Neurogenic bladder evaluation and
management after spinal cord injury: Current practice among urologists
working in Saudi Arabia. Urology Annual; 3(1): 24–28.
42. Homma Y, Batista J, Bauer S et al. (2010), Urodynamics (chap 07);
Neurourology and Urodynamics; 317-372


43. Klausner AP, Steers WD (2011), The Neurogenic Bladder: An Update
with Management Strategies for Primary Care Physicians. Med Clin N Am
95: 111–120
44. Anne P and Cameron AP (2011), The role of ambulatory urodynamics in
spinal cord injury. National Review of Urology; 8: 298–299
45. Schafer W, Abrams P, Liao L et al. (2002), Goodurodynamic practices:
uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol
Urodyn; 21:261–274
46. Stohrer M, Blok B, Castro-Diaz D et al. (2009), EAU Guidelines on
Neurogenic Lower Urinary Tract Dysfunction. European Urology; 56:
81–88
47. Wyndaele J.J (2005), Practical Management of Neurogenic Bladder in
the Spinal Cord Injured Patients. Turk J Phys Med Rehab;51(Suppl B):
B1-B7
48. Corcos J and Schurch B (2006), Use of Botulinum Toxin in Overactive
Bladder. European urology sup plements; 5: 667–669.
49. Grosse J, Kramer G and Jakse G (2009), Comparing two types of

botulinum-A toxin detrusor injections in patients with severe neurogenic
detrusor overactivity: a case-control study. BJU International; 104: 651–
656
50. Tow AM, Toh KL, Chan S-P et al. (2007), Botulinum Toxin Type A for
Refractory Neurogenic Detrusor Overactivity in Spinal Cord Injured
Patients in Singapore. Medicine Singapore; 36:11-7
51. Chapple CR (2012), β3-Agonist Therapy: A New Advance in the
Management of Overactive Bladder? European Urology; 62: 841–842
52. Kanai A, Zabbarova I, Oefelein M et al. (2012), Mechanisms of Action
of Botulinum Neurotoxins, 3-Adrenergic Receptor Agonists, and PDE5
Inhibitors in Modulating Detrusor Function in Overactive Bladders.
Neurourology and Urodynamics 31:300–308


53. Wyndaele J.J, Brauner A, Geerlings SE et al. (2012), Clean intermittent
catheterization and urinary tract infection: review and guide for future
research. BJU Iternational; 110: E910–E917
54. Andersson K-E (2011), Antimuscarinic Mechanisms and the Overactive
Detrusor: Review- Voiding Dysfunction. European Urology; 59: 377–386
55. Reitz A, Stohrerb M , Kramer G, et al. (2004), European Experience of
200 Cases Treated with Botulinum-A Toxin Injections into the
DetrusorMuscle for Urinary Incontinence due to Neurogenic Detrusor
Overactivity. European Urology; 45: 510–515.
56.

Klaphajone

J,

Kitisomprayoonkul

W,

Sriplakit

S

(2005),

Toxin Type A Injections for Treating Neurogenic Detrusor Overactivity
Combined With Low-Compliance Bladder in Patients With Spinal Cord
Lesions; Arch Phys Med Rehabil; 86: 2114-8
57. O’Leary M, Dierich M (2010), Botulinum Toxin Type A for the
Treatment of Urinary Tract Dysfunction in Neurological Disorders.
Urologic Nursing; Volume 30, Number 4: 228-233.
58. Ruffion A, Capelle O, Parapel P et al. (2006), What is the optimum dose
of type A botulinum toxin for treating neurogenic bladder overactivity?
BJU Int; 97: 1030-4
59. Schurch B, Schulte-Baukloh H (2006), Botulinum Toxin in the
Treatment of Neurogenic Bladder in Adults and Children. European
urology supplements 5: 679–684
60. Krebs J, and Pannek J (2013), Effects of solifenacin in patients with
neurogenic detrusor overactivity as a result of spinal cord lesion. Spinal
Cord; 51: 306–309
61. Visco AG, Brubaker L, Richter HE et al. (2012), Anticholinergic
Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence. N
Engl J Med; 367:1803-13


62. Carruthers A, Carruthers J (2013), Botulinum toxin. Elservier Saunders:

1-26
63. Truong D (2009), Manual of Botulinum toxin therapy. Cambridge
university Press, New York:1-23
64. Moore AP (1995), “Handbook of Botulinum Toxin Treatment”,
Blackwell Science Ltd, Oxford
65. Patel AK, Patterson JM, Chapple CR (2006), Botulinum Toxin Injections
for Neurogenic and Idiopathic Detrusor Overactivity: A Critical Analysis
of Results. European urology 50: 684–710.
66. MacDonald R, Fink HA, Huckabay C (2007), Botulinum toxin for
treatment of urinary incontinence due to detrusor overactivity: a
systematic review of effectiveness and adverse effects. Review, Spinal
Cord 45: 535–541
67. Hori S, Patki P, Attar KH et al. (2009), Patients’ perspective of
botulinum toxin-A as a long-term treatment option for neurogenic
detrusor overactivity secondary to spinal cord injury; BJU Internatinal;
104: 216–220
68. Gamé X, Castel-Lacanal E, Bentaleb Y et al (2008), Botulinum toxin A
detrusor injections in patients with neurogenic detrusor overactivity
significantly decrease the incidence of symptomatic urinary tract
infections. Eur Urol; 53:613–618
69. Novara G (2008), Botulinum toxin A detrusor injections inn patients with
neurogenic detrusor overactivity singificantly decrease the incidence of
symptomatic urinary tract infection. European Urology 53: 618-619
70. Abdel-Meguid TA (2010), Botulinum Toxin-A Injections Into
Neurogenic Overactive Bladder - To Include or Exclude the Trigone? A
Prospective, Randomized, Controlled Trial. The Journal of Urology; Vol.
184, 2423-2428


71. Wefer B, Ehlken B, Bremer J et al. (2010), Treatment outcomes and

resource use of patients with neurogenic detrusor overactivity receiving
botulinum toxin A (BOTOX®) therapy in Germany. World J Urol; 28:
385–390
72. Kulaksizolu (2010), Botulinum Toxin Applications in Overactive
Bladder Symptoms Secondary to Neurological Diseases; Archives of
Neuropsychiatry; 47 Supplement: 44-7
73.Herschorn S, Gajewski J, Ethans K et al (2011), Efficacy of botulinum
toxin A injection for neurogenic detrusor overactivity and urinary
incontinence: a randomized, double-blind trial. JUrol; 185: 2229–2235
74. Schulte-Baukloh H (2012), Botulinum toxin for neurogenic bladder
dysfunction; Urologe; 51:198–203
75. Del Popolo G (2008), Botulinum Toxin A Era: Little Steps Towards a
Better Understanding. European Urology 54: 25–27
76. Médée B, RuffionA (2009), Intérêt et résultats de l’utilisation de la
toxine

botulique

dans

l’hyperactivité

détrusorienne

d’origine

neurologique. Pelv Perineol; 4: 60-66
77. Nitti V.W (2006), Botulinum Toxin for the Treatment of Idiopathic and
Neurogenic Overactive Bladder: State of the Art. Reviews in urology, vol.
8; No. 4: 198-206

78. Rapp DE, Lucioni A, Bales GT (2007), Botulinum toxin injection: a
review of injection principles and protocols. Int Braz J Urol; 33(2):132–
141
79. Ehren I, Volz D,

Farrelly E et al. (2007), Efficacy and impact of

botulinum toxin A on quality of life in patients with neurogenic detrusor
overactivity: A randomized, placebo-controlled, double-blind study.
Scandinavian Journal of Urology and Nephrology; 41: 335-340
80. Kennelly M, Dmochowski R, Ethans K et al. (2013), Long-term Efficacy
and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence


Due to Neurogenic Detrusor Overactivity: An Interim Analysis. Urology;
81: 491- 497
81. Curcio L, Costa F, Marinho MA et al. (2008), Use of Botulinum Toxin
Type A (Botox®) Through Transcystoscopic Vesical Insertion for
Overactive Bladder Syndrome Non-Responsive to Oral Medication or for
Parasympatholytic Drugs use Severe Side Effects. Braz. J. Video-Sur, v.
1, n. 3: 097-103.
82. Chuang YC, Kuo H-C and Chancellor MB (2010), Botulinum toxin for
the lower urinary tract; review article; BJU International; 105: 1046 –
1058
83. Chen C-Y, Liao C-H, Kuo H-C et al. (2011), Therapeutic effects of
detrusor botulinum toxin A injection on neurogenic detrusor overactivity
in patients with different levels of spinal cord injury and types of detrusor
sphincter dyssynergia. Spinal Cord; 49: 659–664
84. Del Popolo G , Filocamo MT, Marzi VL et al. (2008), Neurogenic
Detrusor Overactivity Treated with English Botulinum Toxin A: 8-Year

Experience of One Single Centre. European Urology; 53: 1013–1020
85. Kalsi V, Apostolidis A, Gonzales G et al. (2008), Early Effect on the
Overactive Bladder Symptoms following Botulinum Neurotoxin Type A
Injections for Detrusor Overactivity. European Urology; 54: 181–187
86. MacDiarmid S, Anderson RU, Armstrong RB et al. (2005), Efficacy and
safety of extended release oxybutynin for the treatment of urge
incontinence: an analysis of data from 3 flexible dosing studies. The
Journal of urology; vol. 174 (1), no4,1301-1305(P1=0,46%)
87. Hubsher CP and Costa J (2009), Urologic Management of a Patient with
Neuropathic Voiding Dysfunction. Northeast Florida Medicine Vol. 60,
No. 3: 13-17


88. Bothig R, Fiebag K, Thietje R et al. (2013), Morbidity of urinary tract
infection after urodynamic examination of hospitalized SCI patients: the
impact of bladder management. Spinal Cord; 51, 70–74
89. Pannek J, Nehiba M et al. (2007), Morbidity of urodynamic testing in
patients with spinal cord injury: is antibiotic prophylaxis necessary?
Spinal Cord; 45: 771–774
90. Krhut J, Samal V, Nemec D et al. (2012), Intradetrusor versus
suburothelial onabotulinumtoxin A injections for neurogenic detrusor
overactivity: a pilot study. Spinal Cord; 50: 904–907
91. Okamura K, Nojiri Y, Ameda K et al. (2011), Botulinum toxin A
submucosal injection for refractory non-neurogenic overactive bladder:
Early outcomes. International Journal of Urology 18: 483–487
92. Jeffery S, Fynes M, Lee F et al. (2007), Efficacy and complications of
intradetrusor injection with botulinum toxin A in patients with refractory
idiopathic detrusor overactivity. BJU International; (100): 1302–1306
93. Kirshblum SC, Burns SP, Biering-Sorensen F, et al. (2011),
International standards for neurological classification of spinal cord

injury; J Spinal Cord Med;34(6):535–46.
94.Apostolidis A, Popat R, Harper M et al. (2007), Successful treatment with
botulinum toxin A after failed augmentation ileocystoplasty. Nature
Clinical Practice Urology; 4 (5): 280-284.
95. Chen G, Liao L (2011), Injections of Botulinum Toxin A into the detrusor
to treat neurogenic detrusor overactivity secondary to spinal cord injury;
Int Urol Nephrol; 43:655–662
96. Gray M (2011), Traces: Making Sense of Urodynamics Testing – Part 4:
Preparing the Patient for Multichannel Urodynamics Testing. Urologic
Nursing; Volume 31 Number 2: 71-77.


97. Gray M (2012), Traces: Making Sense of Urodynamics Testing – Part 9:
Evaluation of Detrusor Response To Bladder Filling. Urologic Nursing;
Volume 32 Number 1: 21-28.
98. Khanna CR, Sandhu CAS, Doddamani CD (2009), Urodynamic
management of Neurogenic Bladder in Spinal Cord Injury. MJAFI, Vol.
65: 300-304
99. Suzuki Bellucci CH, Wöllner J, Gregorini F et al. (2012), Neurogenic
Lower Urinary Tract Dysfunction—Do We Need Same Session Repeat
Urodynamic Investigations? The Journal of Urology; Vol. 187, 13181323
100. Jia C, Liao L-M, Chen G et al. (2013), Detrusor botulinum toxin A
injection significantly decreased urinary tract infection in patients with
traumatic spinal cord injury. Spinal Cord; 51: 487–490
101. Akkoca Y, Cinar Y and Kismali E (2012), Should complete and
incomplete spinal cord injury patients receive the same attention in
urodynamic evaluations and ultrasonography examinations of the upper
urinary tract? International Journal of Rehabilitation Research, Vol 35
No 2: 178-180
102. Ginsberg D, Gousse A, Keppenne V et al. (2012), Phase 3 Efficacy and

Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence
From Neurogenic Detrusor Overactivity. The journal of urology; Vol.
187: 2131-2139
103. Đỗ Đào Vũ, Cao Minh Châu (2006), Bước đầu đánh giá hiệu quả phục
hồi chức năng cho bệnh nhân liệt tứ chi sau chấn thương cột sống cổ.
Luận văn tốt nghiệp bác sỹ nội trú, Đại học Y Hà Nội
104. Cầm Bá Thức, Nguyễn Xuân Nghiên, Cao Minh Châu (2008), Nghiên
cứu thực trạng bệnh nhân liệt hai chi dưới do chấn thương tủy sống tại
cộng đồng và đề xuất một số giải pháp can thiệp. Luận văn tốt nghiệp tiến
sỹ y khoa, Đại học Y Hà Nội


105. Lombardi G, Celso M, Mencarini M et al. (2013), Clinical efficacy of
intravesical electrostimulation on incomplete spinal cord patients
suffering from chronic neurogenic non-obstructive retention: a 15-year
single centre retrospective study. Spinal Cord; 51: 232–237
106. Furusawa K, Tokuhiro A, Sugiyama H et al. (2011), Incidence of
symptomatic autonomic dysreflexia varies according to the bowel and
bladder management techniques in patients with spinal cord injury. Spinal
Cord; 49: 49–54
107. Nosseir M, Hinkel A, and Pannek J (2007), Clinical Usefulness of
Urodynamic Assessment for Maintenance of Bladder Function in
PatientsWith Spinal Cord Injury. Neurourology and Urodynamics 26:
228-233
108. Luo D-Y, Ding M-F, He C-Q et al. (2012), Bladder management of
patients with spinal cord injuries sustained in the 2008 Wenchuan
earthquake. Kaohsiung Journal of Medical Sciences; 28: 613-618
109. Birzele J, Mehnert U, Reuter K et al. (2009), Preserving voiding
function and alleviation of Overactive Bladder symptoms with 100 units
of Botulnum neurotoxin A, In multiple Sclerosis patients: a Promising

therapy? Eur Urol Suppl;8(4):242
110. Conté A, Giannantoni A, Proietti S, et al. (2012), Botulinum toxin A
modulates afferent fibers in neurogenic detrusor overactivity. European
Journal of Neurology, 19: 725–732
111. Stohrer M, Murtz G, Kramer G et al. (2007), Propiverine Compared to
Oxybutynin in Neurogenic Detrusor Overactivity – Results of a
Randomized, Double-blind, Multicenter Clinical Study. European
Urology; 5: 235–242
112. Kessler TM, Khan S, Panicker J et al. (2009), Clean Intermittent SelfCatheterization After Botulinum Neurotoxin Type A Injections ShortTerm Effect on Quality of Life. Obstet Gynecol;113:1046–51


113. Michel MC, Chapple CR (2009), Basic Mechanisms of Urgency:

Preclinical and Clinical Evidence. European Urology; 56: 298–308
114. Chen S-L, Bih L-I, Huang Y-H et al. (2008), Effect of single
Botulinum toxin A injection to the external urethral sphincter for treating
detrusor external sphincter dyssynergia in spinal cord injury. Journal of
Rehabilitation Medicine; 40: 744–748
115. Gamé X, Chartier-Kastler E, Ayoub N et al. (2008), Outcome after
treatment of detrusor–sphincter dyssynergia by temporary stent. Spinal
Cord 46: 74–77
116. Rickey LM, Kenton K (2008), Botulinum Toxin: New Option for
Refractory Lower Urinary Tract Symptoms in Women. Clinical
Obstetrics and Gynecology; Volume 51, Number 1, 176–186
117. Bersch U, Gocking K, Pannek J (2009), The Artificial Urinary
Sphincter in Patients with Spinal Cord Lesion: Descriptionof Modified
Technique and Clinical Results. European Urology 55: 687–695
118. Schulte-Baukloha H, Weißa C, Stolzea T et al. (2005), BotulinumAToxin Detrusor and Sphincter Injection in Treatment of Overactive
Bladder Syndrome: Objective Outcome and Patient Satisfaction.
European Urology; 48: 984–990

119. Safari S, Jamali S, Habibollahi P et al. (2010), Intravesical Injections of
Botulinum Toxin Type A for Management of Neuropathic Bladder: A
Comparison of Two Methods. Urology; 76: 225–232
120. Gallien P, Durufle A, Nicolas B et al. (2009), Indication et résultats de
la toxine botulique en injection intrasphinctérienne dans les dysuries
d’origine neurologique. Pelv Perineol 4: 67-71
121. Đỗ Đào Vũ, Lương Tuấn Khanh, Cao Minh Châu (2013), Rối loạn
phản xạ tự động tủy trong thăm dò niệu động học ở bệnh nhân tổn thương
tủy sống.Tạp chí y học thực hành Bệnh viện Bạch Mai; số 74 Tr 53-60.


122. Li X, Song B, Su Y et al. (2012), High bladder pressure during urine
storage is a main reason of upper urinary tract damage by voiding
dysfunction diseases. Pak J Med Sci

July – September; Vol. 28 No. 4

716-721
123. Yokoyama T, Chancellor MB, Oguma K et al. (2012), Botulinum toxin
type A for the treatment of lower urinary tract disorders. International
Journal of Urology; 19: 202–215
124. Alloussi S.H, Lang Ch, Eichel R et al. (2012), Videourodynamic
changes of botulinum toxin A in patients with neurogenic bladder
dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory
to drug treatment. World J Urol; 30:367–373
125. Karsenty G, Denys P, Amarenco G, et al. (2008), Botulinum toxin A
(Botox) intradetrusor injections in adults with neurogenic detrusor
overactivity/neurogenic overactive bladder: a systematic literature review.
Eur Urol; 53(2): 275–287
126. Cruz F, Herschorn S, Aliotta P et al. (2011), Efficacy and safety of

onabotulinumtoxinA in patients with urinary incontinence due to
neurogenic detrusor overactivity: A randomised, double-blind, placebocontrolled trial. Eur Urol; 60: 742–750
127. Elkelini MS, Bagli DJ, Fehlings M et al. (2011), Effects of intravesical
onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia
after spinal cord injury: role of nerve growth factor. BJU International;
109: 402–407
128. Watanabe M, Yamanishi T, Honda M et al. (2010), Efficacy of
extended-release tolterodine for the treatment of neurogenic detrusor
overactivity and/or low-compliance bladder. International Journal of
Urology; 17: 931–936


129. Fowier CJ (2011), Systematic review of therapy for neurogenic
detrusor overactivity. Therapy for neurogenic detrusor overactivity; Can
Urol Assoc ;5(Suppl 2): S146-S148
130. Jeong SJ, Lee SC, Jeong CW et al. (2013), Clinical and urodynamic
differences among women with overactive bladder according to the
presence of detrusor overactivity. Int Urogynecol J 24:255–261
131. Schurch B, Denys P, Kozma CM et al. (2007), Reliability and validity
of the incontinece quality of life questionnaire in Patients with
Neurogenic Urinary Incontinence. Arch phys med rehabil; vol 88: 646652
132. De Leaf K, Wyndaele J-J (2005), Adverse events after botulinum A
toxin injection for neurogenic voiding disorders. Spinal Cord; 43: 397-9